bit.bio

bit.bio designs and manufactures human cells to advance drug discovery and biomedical research, enabling transformative treatments in human health. Using our proprietary cell identity coding platform, we have the ability to create any human cell type and to manufacture it at scale with precision and consistency. The platform consists of two key aspects: the first being its AI powered discovery platform which identifies unique combinations of transcription factors that can program any desired cell identity, and the second being the precise control and robust expression of those transcription factors in induced pluripotent stem cells (iPSCs), executed by opti-ox deterministic cell programming. With opti-ox, we rapidly and precisely convert iPSCs into any desired human cell type in a single manufacturing step.  

bit.bio partners with innovators to enable access to our platform for the development of the next generation of allogeneic cell therapies and to date, bit.bio has a wide portfolio of cryopreserved products, ioCells, ready to ship globally.

The ioCells portfolio features 45 products, including ioWild Type Cells, ioDisease Model Cells, ioTracker Cells and CRISPR-Ready ioCells.

bit.bio leverages the ioCells portfolio to generate custom disease models and to conduct CRISPR screening with a range of readouts including high-throughput viability assays, fluorescence-based phenotypic screens, next-generation sequencing (NGS) to identify gene knockout effects and single-cell RNA sequencing.

Since spinning out from the University of Cambridge and launching in 2016, we have raised approximately $225m from leading investors, including Arch Venture, Blueyard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent.